WallStreetZenWallStreetZen

NASDAQ: ELEV
Elevation Oncology Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for ELEV

Based on 5 analysts offering 12 month price targets for Elevation Oncology Inc

Min Forecast
$0.36-5.76%
Avg Forecast
$2.81+636.13%
Max Forecast
$7.00+1,732.46%

Should I buy or sell ELEV stock?

Based on 5 analysts offering ratings for Elevation Oncology Inc.

Hold
Strong Buy
1 analysts 20%
Buy
0 analysts 0%
Hold
4 analysts 80%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ELEV stock forecasts and price targets.

ELEV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-06-10
lockedlocked$00.00+00.00%2025-03-21
lockedlocked$00.00+00.00%2025-03-21
lockedlocked$00.00+00.00%2025-03-21
lockedlocked$00.00+00.00%2025-03-07

1 of 1

Forecast return on equity

Is ELEV forecast to generate an efficient return?

Company
-45.62%
Industry
140.91%
Market
90.47%
ELEV's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ELEV forecast to generate an efficient return on assets?

Company
-25.93%
Industry
32.45%
ELEV is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ELEV earnings per share forecast

What is ELEV's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$0.75
Avg 2 year Forecast
-$0.44
Avg 3 year Forecast
-$0.48

ELEV revenue forecast

What is ELEV's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$11.2M
Avg 2 year Forecast
$50.7M
Avg 3 year Forecast
$198.1M

ELEV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ELEV$0.38$2.81+636.13%Hold
CMMB$1.20$8.50+608.33%Strong Buy
VOR$0.18$8.00+4,295.60%Buy
IPA$0.70$4.00+469.80%Buy
RLMD$0.70N/AN/A
View Top Biotech Stocks

Elevation Oncology Stock Forecast FAQ

Is Elevation Oncology Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: ELEV) stock is to Hold ELEV stock.

Out of 5 analysts, 1 (20%) are recommending ELEV as a Strong Buy, 0 (0%) are recommending ELEV as a Buy, 4 (80%) are recommending ELEV as a Hold, 0 (0%) are recommending ELEV as a Sell, and 0 (0%) are recommending ELEV as a Strong Sell.

If you're new to stock investing, here's how to buy Elevation Oncology stock.

What is ELEV's earnings growth forecast for 2025-2027?

(NASDAQ: ELEV) Elevation Oncology's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.33%.

Elevation Oncology's earnings in 2025 is -$47,989,000.On average, 6 Wall Street analysts forecast ELEV's earnings for 2025 to be -$44,613,235, with the lowest ELEV earnings forecast at -$59,223,729, and the highest ELEV earnings forecast at -$36,718,712. On average, 6 Wall Street analysts forecast ELEV's earnings for 2026 to be -$26,058,441, with the lowest ELEV earnings forecast at -$33,757,526, and the highest ELEV earnings forecast at -$17,767,119.

In 2027, ELEV is forecast to generate -$28,545,837 in earnings, with the lowest earnings forecast at -$36,126,475 and the highest earnings forecast at -$23,097,254.

What is ELEV's revenue growth forecast for 2027-2029?

(NASDAQ: ELEV) Elevation Oncology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.

Elevation Oncology's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast ELEV's revenue for 2027 to be $660,699,921, with the lowest ELEV revenue forecast at $51,524,644, and the highest ELEV revenue forecast at $1,486,515,598. On average, 1 Wall Street analysts forecast ELEV's revenue for 2028 to be $3,000,866,348, with the lowest ELEV revenue forecast at $3,000,866,348, and the highest ELEV revenue forecast at $3,000,866,348.

In 2029, ELEV is forecast to generate $11,732,812,952 in revenue, with the lowest revenue forecast at $11,732,812,952 and the highest revenue forecast at $11,732,812,952.

What is ELEV's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: ELEV) forecast ROA is -25.93%, which is lower than the forecast US Biotechnology industry average of 32.45%.

What is ELEV's Price Target?

According to 5 Wall Street analysts that have issued a 1 year ELEV price target, the average ELEV price target is $2.81, with the highest ELEV stock price forecast at $7.00 and the lowest ELEV stock price forecast at $0.36.

On average, Wall Street analysts predict that Elevation Oncology's share price could reach $2.81 by Jun 10, 2026. The average Elevation Oncology stock price prediction forecasts a potential upside of 636.13% from the current ELEV share price of $0.38.

What is ELEV's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: ELEV) Elevation Oncology's current Earnings Per Share (EPS) is -$0.82. On average, analysts forecast that ELEV's EPS will be -$0.75 for 2025, with the lowest EPS forecast at -$1.00, and the highest EPS forecast at -$0.62. On average, analysts forecast that ELEV's EPS will be -$0.44 for 2026, with the lowest EPS forecast at -$0.57, and the highest EPS forecast at -$0.30. In 2027, ELEV's EPS is forecast to hit -$0.48 (min: -$0.61, max: -$0.39).

What is ELEV's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: ELEV) forecast ROE is -45.62%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.